BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guery B, Galperine T, Barbut F. Clostridioides difficile: diagnosis and treatments. BMJ. 2019;366:l4609. [PMID: 31431428 DOI: 10.1136/bmj.l4609] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Abay S, Ahmed EF, Aydin F, Karakaya E, Müştak HK. Presence of Clostridioides difficile in cattle feces, carcasses, and slaughterhouses: Molecular characterization and antibacterial susceptibility of the recovered isolates. Anaerobe 2022;:102575. [PMID: 35477095 DOI: 10.1016/j.anaerobe.2022.102575] [Reference Citation Analysis]
2 Navalkele BD, Polistico J, Sandhu A, Awali R, Krishna A, Chandramohan S, Tillotson G, Chopra T. Clinical outcomes after faecal microbiota transplant by retention enema in both immunocompetent and immunocompromised patients with recurrent Clostridioides difficile infections at an academic medical centre. J Hosp Infect 2020;106:643-8. [PMID: 32991940 DOI: 10.1016/j.jhin.2020.09.027] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Emberger J, Hitchcock MM, Markley JD. Diagnostic Stewardship Approaches to Clostridioides difficile Infection in the Era of Two-Step Testing: a Shifting Landscape. Curr Treat Options Infect Dis 2020;12:258-74. [DOI: 10.1007/s40506-020-00223-8] [Reference Citation Analysis]
4 Sullivan MH, Boggiano VL, Smith KL. Management of difficult-to-treat Clostridioides difficile in a patient with chronic osteomyelitis. BMJ Case Rep 2020;13:e233095. [PMID: 32229549 DOI: 10.1136/bcr-2019-233095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fuchs M, Lamm-Schmidt V, Sulzer J, Ponath F, Jenniches L, Kirk JA, Fagan RP, Barquist L, Vogel J, Faber F. An RNA-centric global view of Clostridioides difficile reveals broad activity of Hfq in a clinically important gram-positive bacterium. Proc Natl Acad Sci U S A 2021;118:e2103579118. [PMID: 34131082 DOI: 10.1073/pnas.2103579118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Siciliano V, Nista EC, Rosà T, Brigida M, Franceschi F. Clinical Management of Infectious Diarrhea. Rev Recent Clin Trials 2020;15:298-308. [PMID: 32598272 DOI: 10.2174/1574887115666200628144128] [Reference Citation Analysis]
7 Szabo BG, Duma L, Lenart KS, Kiss R, Vad E, Petrik BR, Ostorhazi E, Kadar B. Characteristics and predictors of treatment failure with intravenous tigecycline monotherapy among adult patients with severe Clostridioides (Clostridium) difficile infection: a single-centre observational cohort study. Diagn Microbiol Infect Dis 2021;99:115231. [PMID: 33099134 DOI: 10.1016/j.diagmicrobio.2020.115231] [Reference Citation Analysis]
8 Du H, Siah KTH, Ru-Yan VZ, Teh R, En Tan CY, Yeung W, Scaduto C, Bolongaita S, Cruz MTK, Liu M, Lin X, Tan YY, Feng M. Prediction of in-hospital mortality of Clostriodiodes difficile infection using critical care database: a big data-driven, machine learning approach. BMJ Open Gastroenterol 2021;8:e000761. [PMID: 34789472 DOI: 10.1136/bmjgast-2021-000761] [Reference Citation Analysis]
9 Bhaskara V, Leal MT, Seigner J, Friedrich T, Kreidl E, Gadermaier E, Tesarz M, Rogalli A, Stangl L, Wallwitz J, Hammel K, Rothbauer M, Moll H, Ertl P, Hahn R, Himmler G, Bauer A, Casanova E. Efficient production of recombinant secretory IgA against Clostridium difficile toxins in CHO-K1 cells. J Biotechnol 2021;331:1-13. [PMID: 33689865 DOI: 10.1016/j.jbiotec.2021.02.013] [Reference Citation Analysis]
10 Fettucciari K, Fruganti A, Marchegiani A, Brancorsini S, Marconi P, Bassotti G. Proinflammatory Cytokines: Possible Accomplices for the Systemic Effects of Clostridioides difficile Toxin B. J Inflamm Res 2021;14:57-62. [PMID: 33469335 DOI: 10.2147/JIR.S287096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dudzicz S, Wiecek A, Adamczak M. Clostridioides difficile Infection in Chronic Kidney Disease-An Overview for Clinicians. J Clin Med 2021;10:E196. [PMID: 33430465 DOI: 10.3390/jcm10020196] [Reference Citation Analysis]
12 Azimirad M, Krutova M, Yadegar A, Shahrokh S, Olfatifar M, Aghdaei HA, Fawley WN, Wilcox MH, Zali MR. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. Emerg Microbes Infect 2020;9:1432-43. [PMID: 32520657 DOI: 10.1080/22221751.2020.1780949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 de Jager P, Smith O, Bolon S, Thomas J, Richards GA. Epidemiology of Clostridioides difficile in South Africa. PLoS One 2021;16:e0259771. [PMID: 34813626 DOI: 10.1371/journal.pone.0259771] [Reference Citation Analysis]
14 Gnocchi M, Gagliardi M, Gismondi P, Gaiani F, De' Angelis GL, Esposito S. Updated Management Guidelines for Clostridioides difficile in Paediatrics. Pathogens 2020;9:E291. [PMID: 32316346 DOI: 10.3390/pathogens9040291] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Smith-Peter E, Séguin DL, St-Pierre É, Sekulovic O, Jeanneau S, Tremblay-Tétreault C, Lamontagne AM, Jacques PÉ, Lafontaine DA, Fortier LC. Inactivation of the riboswitch-controlled GMP synthase GuaA in Clostridioides difficile is associated with severe growth defects and poor infectivity in a mouse model of infection. RNA Biol 2021;:1-12. [PMID: 34612173 DOI: 10.1080/15476286.2021.1978768] [Reference Citation Analysis]
16 Abad CLR, Safdar N. A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea. Gastroenterol Clin North Am 2021;50:323-40. [PMID: 34024444 DOI: 10.1016/j.gtc.2021.02.010] [Reference Citation Analysis]
17 Bassotti G, Marchegiani A, Marconi P, Fettucciari K. The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses. Microbiologyopen 2020;9:e1061. [PMID: 32657021 DOI: 10.1002/mbo3.1061] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Mateu L, Fernández-Rivas G, Sopena N. Diagnosis and treatment of Clostridioides difficile infection. Med Clin (Barc) 2020;155:30-5. [PMID: 32430207 DOI: 10.1016/j.medcli.2020.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Baunwall SMD, Dahlerup JF, Engberg JH, Erikstrup C, Helms M, Juel MA, Kjeldsen J, Nielsen HL, Nilsson AC, Rode AA, Vinter-Jensen L, Hvas CL. Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scand J Gastroenterol 2021;56:1056-77. [PMID: 34261379 DOI: 10.1080/00365521.2021.1922749] [Reference Citation Analysis]
20 Granata G, Mariotti D, Ascenzi P, Petrosillo N, di Masi A. High Serum Levels of Toxin A Correlate with Disease Severity in Patients with Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:1093. [PMID: 34572675 DOI: 10.3390/antibiotics10091093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yue B, Yu ZL, Lv C, Geng XL, Wang ZT, Dou W. Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease. World J Gastroenterol 2020; 26(30): 4378-4393 [PMID: 32874052 DOI: 10.3748/wjg.v26.i30.4378] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Yoon S, Hong J, Park B, Choi Y, Khan MS, Hwang J, Tanaka M, Choi J. Oxygen transport to mammalian cell and bacteria using nano-sized liposomes encapsulating oxygen molecules. J Biosci Bioeng 2021;132:657-65. [PMID: 34538590 DOI: 10.1016/j.jbiosc.2021.08.010] [Reference Citation Analysis]
23 Lenggenhager L, Zanella MC, Poncet A, Kaiser L, Schrenzel J. Discordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland. BMJ Open 2020;10:e036342. [PMID: 32928850 DOI: 10.1136/bmjopen-2019-036342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lamm-schmidt V, Fuchs M, Sulzer J, Gerovac M, Hör J, Dersch P, Vogel J, Faber F. Grad-seq identifies KhpB as a global RNA-binding protein in Clostridioides difficile that regulates toxin production. microLife 2021;2:uqab004. [DOI: 10.1093/femsml/uqab004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
25 Paschos P, Ioakim K, Malandris K, Koukoufiki A, Nayfeh T, Akriviadis E, Tsapas A, Bekiari E. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Anaerobe 2021;71:102441. [PMID: 34454094 DOI: 10.1016/j.anaerobe.2021.102441] [Reference Citation Analysis]
26 Li T, Lyu L, Zhang Y, Dong K, Li Q, Guo X, Zhu Y. A newly isolated E. thailandicus strain d5B with exclusively antimicrobial activity against C. difficile might be a novel therapy for controlling CDI. Genomics 2021;113:475-83. [PMID: 32956846 DOI: 10.1016/j.ygeno.2020.09.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Knippel RJ, Wexler AG, Miller JM, Beavers WN, Weiss A, de Crécy-Lagard V, Edmonds KA, Giedroc DP, Skaar EP. Clostridioides difficile Senses and Hijacks Host Heme for Incorporation into an Oxidative Stress Defense System. Cell Host Microbe 2020;28:411-421.e6. [PMID: 32526159 DOI: 10.1016/j.chom.2020.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
28 Shao H, Zhang C, Xiao N, Tan Z. Gut microbiota characteristics in mice with antibiotic-associated diarrhea. BMC Microbiol 2020;20:313. [PMID: 33059603 DOI: 10.1186/s12866-020-01999-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Oka D, Yamaya N, Kuno T, Asakawa Y, Shiragiku T, Chen L, Xue J, Mamuti A, Ye F, Sun J, Ohguro K, Miyamoto H, Uematsu Y, Inagaki K, Cheng JF, Matsumoto M. In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile. Antimicrob Agents Chemother 2021;65:e01170-20. [PMID: 33495229 DOI: 10.1128/AAC.01170-20] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]